Novartis AG (NYSE: NVS) Q2 2023 earnings call dated Jul. 18, 2023 Corporate Participants: Samir Shah -- Global Head, Investor Relations Vasant (Vas) Narasimhan -- Chief
Novartis AG
-(NVS)
XNYS:NVS
Novartis AG (NVS) Q1 2023 Earnings Call Transcript
Novartis AG (NYSE:NVS) Q1 2023 Earnings Call dated Apr. 25, 2023. Corporate Participants: Samir Shah — Global Head of Investor Relations Vasant Narasimhan — Chief Executive
Novartis AG (NVS) Q4 2022 Earnings Call Transcript
Novartis AG (NYSE: NVS) Q4 2022 earnings call dated Feb. 01, 2023 Corporate Participants: Samir Shah -- Global Head of Investor Relations Vas Narasimhan -- Chief
Novartis AG (NVS) Q3 2022 Earnings Call Transcript
Novartis AG (NYSE: NVS) Q3 2022 earnings call dated Oct. 25, 2022 Corporate Participants: Samir Shah -- Global Head of Investor Relations Vasant Narasimhan -- Chief
Novartis AG (NVS) Q2 2022 Earnings Call Transcript
Novartis AG (NYSE: NVS) Q2 2022 earnings call dated Jul. 19, 2022 Corporate Participants: Samir Shah -- Global Head of Investor Relations Vasant (Vas)
Novartis AG (NVS) Q2 2021 Earnings Call Transcript
Novartis AG (NYSE: NVS) Q2 2021 earnings call dated Jul. 21, 2021 Corporate Participants: Samir Shah -- Global Head of Investor Relations
Earnings calendar for the week of July 19
Despite strong trading and encouraging news from the labor market, benchmark stock indexes pulled back after making modest gains early in the
Novartis International AG (NVS) Q4 2020 Earnings Call Transcript
Novartis International AG (NYSE: NVS) Q4 2020 earnings call dated Jan. 26, 2021 Corporate Participants: Samir Shah -- Global Head, Investor Relations and Global
Novartis International AG (NVS) Q2 2020 Earnings Call Transcript
Novartis International AG (NYSE: NVS) Q2 2020 earnings call dated Jul. 21, 2020 Corporate Participants: Samir Shah -- Global Head of Investor Relations Vasant
Novartis International AG (NYSE: NVS) Q1 2020 Earnings Call Transcript
Novartis International AG (NVS) Q1 2020 earnings call dated Apr. 28, 2020 Corporate Participants: Samir Shah -- Global Head of Investor Relations Vasant Narasimhan -- Chief
Novartis scores another point in multiple sclerosis therapy, stock rises
Swiss pharmaceutical giant Novartis International AG (NYSE: NVS) on Friday said its ofatumumab met the primary and secondary endpoints of Phase 3
What the future holds for generic drug industry
The size of the generic drug market in the US is so large that about 90% of all prescription medicines sold last
Novartis’ one-time gene therapy for spinal muscular atrophy gets FDA nod
Picture Courtesy: Novartis Zolgensma, a gene-based treatment from Novartis (NYSE: NVS) for the treatment of spinal muscular atrophy that affects newborns, received
Tilray earnings preview: Investors need more than just production expansion
Though the marijuana industry has been seeing overall tremendous growth, one prominent name has been pulling it down – Tilray (NASDAQ: TLRY).
Intercept Pharmaceuticals reports mixed Q1 results
Intercept Pharmaceuticals (NASDAQ: ICPT) reported wider-than-expected losses in the first quarter of 2019, primarily due to higher R&D expenses related to NASH
Amarin earnings preview: Expect higher revenues, but wider losses in Q1
Amarin Corporation (NASDAQ: AMRN) is scheduled to report first-quarter 2019 earnings results on Wednesday, May 1, before the opening bell. Analysts expect the
Novartis (NVS) stock falls after Alcon spin-off; predicts stable growth ahead
Nearly a year after laying out its transformation strategy, with focus on demerging underperforming business units, Novartis (NYSE: NVS) Tuesday said it
Axsome Therapeutics stock climbs to 34-month high
After the slump on weak quarterly results, investors turned positive on Axsome Therapeutics (AXSM) stock, which climbed to the 34-month high of
Tilray rides on successful cannabis harvest in Europe
Tilray’s (TLRY) stock made strong gains early Wednesday after the Canadian marijuana giant said its European arm had a very successful cannabis
Amarin’s stock gains after Q4 revenues beat expectations
Amarin Corporation (AMRN) surpassed analysts’ expectations on revenues for the fourth quarter of 2018 while net loss came in higher-than-expected. Shares rose
Earnings preview: Amarin likely to deliver strong Q4 results
Amarin Corporation (AMRN) is scheduled to report earnings results for the fourth quarter of 2018 on Wednesday, February 27, before the market